secwatch.observer — SEC 8-K summary
======================================

Issuer:     DMK PHARMACEUTICALS Corp (—)
CIK:        0000887247
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001387131-23-002294
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants Adamis extension to June 26, 2023 to meet $1 bid price; reverse split required if needed
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel granted extension through June 26, 2023 to evidence compliance with $1.00 bid price rule.
- Conditions include seeking shareholder approval for reverse stock split and effecting it if needed to achieve $1.00 bid for 10 consecutive days.
- Company previously failed to comply by Dec 27, 2022 after two 180-day grace periods.
- CEO mentions strategic and financing alternatives process announced in October 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887247/000138713123002294/0001387131-23-002294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887247/000138713123002294/admp-8k_022123.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-002294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer